UCB presented EADV data and UCB stock trades 30.07 percent below its high

Published on 10/09/2026 at 12:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit EUR 4.27 billion in first-half 2026, up 23.00 percent year over year. UCB stock costs EUR 202.45 on October 9, 2026 versus EUR 202.75.

Key points in brief

UCB presented September 30 EADV data showing 47.40 percent complete lesion resolution in one patient group versus 33.30 percent in another.
First-half 2026 revenue reached EUR 4.27 billion, up 23.00 percent year over year.
UCB stock was trading at EUR 202.45 at Lang & Schwarz on October 9, 2026, down 0.15 percent versus EUR 202.75.
Barclays maintained a Hold rating with a EUR 260.00 price target on October 2, 2026.

Isometrische 3D-Illustration einer Wertschöpfungskette von Labor über Produktion bis zum Krankenhaus — UCB S.A. mit ISIN BE0003739530 dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 202.45 at Lang & Schwarz on October 9, 2026 at 12:56 p.m. CEST, while its stock stood 30.07 percent below the 52-week high of EUR 289.50. On September 30, UCB presented new BIMZELX data at the European Academy of Dermatology and Venereology, including a 47.40 percent complete-lesion resolution rate for patients with the shortest diagnosis duration versus 33.30 percent for those with the longest duration, according to UCB.

Three milestones shape the pipeline

On July 31, 2026, UCB reported first-half revenue of EUR 4.27 billion, up 23.00 percent from the first half of 2025, while net income reached EUR 1.11 billion, up 134.00 percent, according to Simply Wall St. On September 29, 2026, UCB said 207 people with generalized myasthenia gravis completed a survey linked to its AANEM and MGFA scientific-session program, according to UCB. On September 30, 2026, the EADV release added that 30.70 percent of patients were free of all tunnels after one year, versus 14.50 percent at baseline, according to UCB.

What does the evidence mean for growth?

The numbers support UCB's commercial focus on BIMZELX, but they also show why clinical evidence remains central to the investment case. The first-half revenue increase and EUR 1.11 billion net income provide a financial base, while the EADV results supply measurable evidence for earlier treatment in hidradenitis suppurativa.

Analyst expectations remain higher than the market price. According to Markets Insider on October 2, 2026, Barclays maintained a Hold rating and a EUR 260.00 price target. That target is 28.43 percent above the Lang & Schwarz price, a gap that leaves valuation and execution as the key counterweights to the clinical progress.

Next reporting date is February 25

UCB's next substantiated corporate date is February 25, 2027, when it is scheduled to report fiscal-year 2026 results, according to Simply Wall St.

Stock remains below its yearly high

At Lang & Schwarz, UCB was trading at EUR 202.45 on October 9, 2026 at 12:56 p.m. CEST, down 0.15 percent versus the prior close of EUR 202.75. The 52-week range was EUR 198.75 to EUR 289.50 as of October 9, 2026, placing the price 30.07 percent below the high. The further course of trading is shown by the continuously updated real-time quote of UCB stock.